While nausea, vomiting, and diarrhea are the most commonly reported gastrointestinal adverse effects with GLP-1-based therapies (occurring in 15-40% of patients depending on the agent and dose), FDA prescribing information for several of these medications does list dyspepsia (indigestion) and, in some cases, gastroesophageal reflux disease (GERD) as reported adverse reactions
insurance not accepted Providers may limit renewals per request (usually 28-day supply) Only for patients who already have an active GLP-1 prescription Prescriptions from outside providers subject to rejection by provider The pay-per-visit plan includes 14 days of follow-up messaging for side-effect questions or prescription issues
These medications help regulate blood sugar and promote weight loss by reducing appetite and slowing gastric emptying
Our study describes a novel action of GLP-1 signalling in -cells, which stimulates metabolic/bioenergetic reprograming resulting in a high glycolytic/high ATP generating phenotype, as detailed in (Fig
This article uses FDA's public guidance as a consumer due-diligence framework and does not determine whether any specific FeelGood prescription, provider, pharmacy, or program complies with federal or state law
